Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota

CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Lomeli, Barbara K., Galbraith, Hal, Schettler, Jared, Saviolakis, George A., El-Amin, Wael, Osborn, Blaire, Ravel, Jacques, Hazleton, Keith, Lozupone, Catherine A., Evans, Ronald J., Bell, Stacie J., Ochsner, Urs A., Jarvis, Thale C., Baqar, Shahida, Janjic, Nebojsa
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187627/
https://ncbi.nlm.nih.gov/pubmed/31685472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01395-19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados